A novel electron paramagnetic resonance-based assay for prostaglandin H synthase-1 activity

Journal of Inflammation

Volumn 3, Issue , 2006, Pages

  Turnbull, Catriona M ^a   McClure, Danny ^a   Rossi, Adriano G ^b   Megson, Ian L ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 CARBOXY PROXY; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; ISOENZYME; L HYDROXY 3 CARBOXY PYRROLIDINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; PROSTAGLANDIN SYNTHASE; PROSTANOID; SALICYLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; ELECTRON SPIN RESONANCE; IN VITRO STUDY; INFLAMMATION; OXIDATION; SPIN TRAPPING;

EID: 33749619565     PISSN: 14769255     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-3-12     Document Type: Article

References (39)

1. Chandrasekharan NV, Simmons DL: The cyclooxygenases. Genome Biol 2004, 5(9):241.
2. Eling TE, Mason RP, Sivarajah K: The formation of aminopyrine cation radical by the peroxidase activity of prostaglandin H synthase and subsequent reactions of the radical. J Biol Chem 1985, 260(3):1601-1607.
3. Simmons DL, Botting RM, Hla T: Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004, 56(3):387-437.
4. Hoffmann C: COX-2 in brain and spinal cord implications for therapeutic use. Curr Med Chem 2000, 7(11):1113-1120.
5. Vane JR, Botting RM: The mechanism of action of aspirin. Thromb Res 2003, 110(5-6):255-258.
6. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231(25):232-235.
7. Dannhardt G, Kiefer W: Cyclooxygenase inhibitors - current status and future prospects. Eur J Med Chem 2001, 36(2):109-126.
8. DeWitt DL, Smith WL: Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci U S A 1988, 85(5):1412-1416.
9. Roth GJ, Majerus PW: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975, 56(3):624-632.
10. Roth GJ, Stanford N, Majerus PW: Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975, 72(8):3073-3076.
11. Turnbull CM, Cena C, Fruttero R, Gasco A, Rossi AG, Megson IL: Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. Br J Pharmacol 2006, 148(4):517-526.
12. Keeble JE, Moore PK: Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002, 137(3):295-310.
13. Fiorucci S, Del Soldato P: NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis 2003, 35 Suppl 2:S9-19.
14. Cena C, Lolli ML, Lazzarato L, Guaita E, Morini G, Coruzzi G, McElroy SP, Megson IL, Fruttero R, Gasco A: Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. J Med Chem 2003, 46(5):747-754.
15. Cameron AJ: Aspirin and gastric ulcer. Mayo Clin Proc 1975, 50(10):565-570.
16. Seager JM, Hawkey CJ: ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs. Bmj 2001, 323(7323):1236-1239.
17. Wallace JL: Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997, 112(3):1000-1016.
18. Crofford LJ: COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997, 49:15-19.
19. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96(1):272-277.
20. Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med 2004, 351(17):1709-1711.
21. FitzGerald GA: COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003, 2(11):879-890.
22. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K: Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther 2005, 312(3):1206-1212.
23. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC: Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999, 339 (Pt 3):607-614.
24. Kulmacz RJ, Wang LH: Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem 1995, 270(41):24019-24023.
25. Schneider C, Boeglin WE, Brash AR: Human cyclo-oxygenase-1 and an alternative splice variant: contrasts in expression of mRNA, protein and catalytic activities. Biochem J 2005, 385(Pt 1):57-64.
26. Tsai AL, Palmer G, Kulmacz RJ: Prostaglandin H synthase. Kinetics of tyrosyl radical formation and of cyclooxygenase catalysis. J Biol Chem 1992, 267(25):17753-17759.
27. Schreiber J, Foureman GL, Hughes MF, Mason RP, Eling TE: Detection of glutathione thiyl free radical catalyzed by prostaglandin H synthase present in keratinocytes. Study of cooxidation in a cellular system. J Biol Chem 1989, 264(14):7936-7943.
28. Dikalov S, Skatchkov M, Bassenge E: Spin trapping of superoxide radicals and peroxynitrite by 1-hydroxy-3-carboxy-pyrrolidine and 1-hydroxy-2,2,6, 6-tetramethyl-4-oxo-piperidine and the stability of corresponding nitroxyl radicals towards biological reductants. Biochem Biophys Res Commun 1997, 231(3):701-704.
29. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994, 47(1):55-59.
30. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993, 90(24):11693-11697.
31. Wu KK: Aspirin and salicylate: An old remedy with a new twist. Circulation 2000, 102(17):2022-2023.
32. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK: Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A 1999, 96(9):5292-5297.
33. Kulmacz RJ, Lands WE: Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 1985, 260(23):12572-12578.
34. Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res 1996, 45(5):246-253.
35. Noreen Y, Ringbom T, Perera P, Danielson H, Bohlin L: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod 1998, 61(1):2-7.
36. Corazzi T, Leone M, Maucci R, Corazzi L, Gresele P: Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther 2005, 315(3):1331-1337.
37. Roberts LJ, Morrow JD: The generation and actions of isoprostanes. Biochim Biophys Acta 1997, 1345(2):121-135.
38. Wilhelm J: Metabolic aspects of membrane lipid peroxidation. Acta Univ Carol Med Monogr 1990, 137:1-53.
39. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.